X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
oncology (32) 32
index medicus (30) 30
female (28) 28
adult (25) 25
male (25) 25
middle aged (25) 25
aged (24) 24
pyrimidines - therapeutic use (15) 15
sulfonamides - therapeutic use (15) 15
carcinoma, renal cell - drug therapy (13) 13
kidney neoplasms - drug therapy (12) 12
neoplasms - drug therapy (12) 12
pyrimidines - adverse effects (11) 11
sulfonamides - adverse effects (11) 11
aged, 80 and over (10) 10
pazopanib (10) 10
quinazolines - administration & dosage (10) 10
adolescent (9) 9
antineoplastic agents - therapeutic use (9) 9
cancer (9) 9
expression (9) 9
human necessities (9) 9
hygiene (9) 9
medical or veterinary science (9) 9
preparations for medical, dental, or toilet purposes (9) 9
sunitinib (9) 9
prognosis (8) 8
pyrimidines - administration & dosage (8) 8
sulfonamides - administration & dosage (8) 8
tumors (8) 8
antineoplastic agents - adverse effects (7) 7
kidney neoplasms - pathology (7) 7
quinazolines - adverse effects (7) 7
treatment outcome (7) 7
young adult (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
chemotherapy (6) 6
disease-free survival (6) 6
maximum tolerated dose (6) 6
phase i (6) 6
quinazolines - pharmacokinetics (6) 6
research (6) 6
safety (6) 6
therapy (6) 6
angiogenesis (5) 5
angiogenesis inhibitors - therapeutic use (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - pharmacokinetics (5) 5
breast-cancer (5) 5
carcinoma, renal cell - genetics (5) 5
carcinoma, renal cell - mortality (5) 5
clinical trials (5) 5
dose-response relationship, drug (5) 5
drug administration schedule (5) 5
endothelial growth-factor (5) 5
hematology (5) 5
hematology, oncology and palliative medicine (5) 5
kidney neoplasms - genetics (5) 5
kidney neoplasms - mortality (5) 5
pharmacokinetics (5) 5
phase-ii (5) 5
polymorphism, single nucleotide (5) 5
pyrimidines - pharmacology (5) 5
randomized controlled trials as topic (5) 5
antimitotic agents (4) 4
carcinoma, renal cell - pathology (4) 4
chemistry (4) 4
clinical study (4) 4
clinical trials, phase ii as topic (4) 4
clinical trials, phase iii as topic (4) 4
genotype (4) 4
growth (4) 4
heterocyclic compounds (4) 4
interferon-alpha (4) 4
lapatinib (4) 4
metallurgy (4) 4
metastatic breast-cancer (4) 4
neoplasm staging (4) 4
organic chemistry (4) 4
pharmacogenetics (4) 4
pharmacology/toxicology (4) 4
renal cell carcinoma (4) 4
solid tumors (4) 4
sulfonamides - pharmacology (4) 4
survival rate (4) 4
tyrosine kinase inhibitor (4) 4
administration, oral (3) 3
angiogenesis inhibitors - administration & dosage (3) 3
angiogenesis inhibitors - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
bevacizumab (3) 3
biomarkers (3) 3
breast neoplasms - drug therapy (3) 3
carcinoma (3) 3
carcinoma, renal cell - blood (3) 3
carcinoma, renal cell - secondary (3) 3
care and treatment (3) 3
cohort studies (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 722 - 731
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 827 - 837
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2557 - 2564
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2017, Volume 117, Issue 4, pp. 478 - 484
Background: In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we... 
angiogenic factors; prognostic markers; advanced renal cell carcinoma | cytokines | SURVIVAL | prognostic markers | PAZOPANIB | PHASE-III | SORAFENIB | INTERLEUKIN-6 | advanced renal cell carcinoma | CANCER | INTERFERON-ALPHA | ONCOLOGY | GLOBAL EVALUATION TRIAL | angiogenic factors | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Prognosis | Humans | Middle Aged | E-Selectin - blood | Male | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - blood | Interleukin-6 - blood | Aged, 80 and over | Adult | Female | Leukocyte Count | Carcinoma, Renal Cell - drug therapy | Interleukin-8 - blood | Cytokines - blood | Tissue Inhibitor of Metalloproteinase-1 - blood | Carcinoma, Renal Cell - blood | Time-to-Treatment | Carcinoma, Renal Cell - pathology | Neutrophils | Vascular Endothelial Growth Factor A - blood | Hemoglobins - metabolism | Survival Rate | Tumor Burden | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Hepatocyte Growth Factor - blood | Sulfonamides - therapeutic use | L-Lactate Dehydrogenase - blood | Pyrimidines - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Multiplexing | Identification methods | Interleukin | Clinical trials | Criteria | Parameter identification | Tissue inhibitor of metalloproteinase 1 | Metastases | Consortia | Interleukin 6 | Angiogenesis | Biomedical materials | Biocompatibility | Pretreatment | Vascular endothelial growth factor | Interleukin 8 | Enzyme-linked immunosorbent assay | Medical research | Cytokines | Hepatocyte growth factor | Osteopontin | Patients | E-selectin | Inhibitors | Medical prognosis | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation | Clinical Study
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7_suppl, pp. 303 - 303
303 Background: Pazopanib, an oral tyrosine kinase inhibitor of VEGFR, PDGFR and c-Kit, has been approved for the treatment of advanced renal cell cancer... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2015, Volume 21, Issue 2, pp. 365 - 372
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 03/2016, Volume 22, Issue 6, pp. 1371 - 1377
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15_suppl, pp. e15072 - e15072
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2006, Volume 103, Issue 51, pp. 19478 - 19483
A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the... 
Angiogenesis | Cell growth | Receptors | Human umbilical vein endothelial cells | Secretion | Cell lines | Cell adhesion | Endothelial cells | Cells | Tumors | Xenograft mouse model | xenograft mouse model | angiogenesis | MULTIDISCIPLINARY SCIENCES | GROWTH | C-MYC | OVERCOMES DRUG-RESISTANCE | THERAPEUTIC IMPLICATIONS | ANTIANGIOGENESIS | CANCER | MICROARRAY DATA | PROGRESSION | CHEMOTHERAPY | Immunohistochemistry | RNA, Small Interfering - genetics | Immunoprecipitation | Apoptosis - drug effects | Humans | Pyrimidines - metabolism | Multiple Myeloma - drug therapy | Receptors, Vascular Endothelial Growth Factor - metabolism | Microarray Analysis | Gene Expression Regulation, Neoplastic - drug effects | Enzyme-Linked Immunosorbent Assay | Pyrimidines - pharmacology | Multiple Myeloma - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | Blotting, Western | Cell Movement - drug effects | Animals | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Sulfonamides - metabolism | Cell Line, Tumor | Mice | Neovascularization, Pathologic - metabolism | Proto-Oncogene Proteins c-myc - genetics | Endothelial Cells - drug effects | Development and progression | Dosage and administration | Research | Vascular endothelial growth factor | Patient outcomes | Multiple myeloma | Biological Sciences
Journal Article
by Ravaud, A and Barrios, C and Anak, O and Pelov, D and Louveau, A and Alekseev, B and M-H, T and Agarwala, S. S and Yalcin, S and Melichar, B and McDermott, D. F and Drake, C. G and Sznol, M and Choueiri, T. K and Powderly, J. D and Smith, D. C and Wigginton, J. M and Kollia, G and Gupta, A and Atkins, M. B and Donskov, F and Michaelson, M. D and Puzanov, I and Davis, M. P and Bjarnason, G. A and Motzer, R. J and Lin, X and Cohen, D. P and Wiltshire, R and Rini, B. I and Oudard, S and Culine, S and Vieillefond, A and Priou, F and Goldwasser, F and Gravis-Mescam, G and Deplanque, G and Machiels, J. P and Beuzeboc, P and Sonpavde, G and Maughan, B and Boucher, K. M and Fougeray, R and Niegisch, G and Wong, Y and Sridhar, S. S and Sternberg, C. N and Bellmunt, J and Booth, C. M and Siemens, D. R and Li, G and Peng, Y and Tannock, I. F and Berman, D. M and Kong, W and Mackillop, W. J and Selle, F and Fizazi, K and Biron, P and Bui, B and Bay, J and Flechon, A and Dubot, C and Caty, A and Burcoveanu, D and Delva, R and de Revel, T and Miclea, J. M and Gaulet, M and Horn, E and Provent, S and Temby, I and Brindel, I and Khalil, J and Gligorov, J and Lotz, J.- P and Quinn, D. I and Hamid, O and Tsao-Wei, D and Hu, J and Pinski, J and Schuckman, A and Daneshmand, S and Groshen, S and Raghavan, D and Korn, C and Massopust, K and Ketchens, C and Aparicio, A. M and Dorff, T. B and Zurita-Saavedra, A and Liu, Y and Lin, Y and Tran, H. T and Pandite, L. N and Heymach, J. V and Cella, D and Kaiser, K and Beaumont, J and Diaz, J and ... and VEG105192 Team and investigators
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix258 - ix293
Journal Article
Journal Article